Campbell & CO Investment Adviser LLC Takes $1.01 Million Position in Quest Diagnostics Incorporated $DGX

Campbell & CO Investment Adviser LLC bought a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,289 shares of the medical research company’s stock, valued at approximately $1,008,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DGX. G&S Capital LLC bought a new stake in Quest Diagnostics in the second quarter worth $1,262,000. Pacer Advisors Inc. boosted its stake in Quest Diagnostics by 2,531.6% in the 3rd quarter. Pacer Advisors Inc. now owns 450,898 shares of the medical research company’s stock worth $85,932,000 after purchasing an additional 433,764 shares in the last quarter. Aaron Wealth Advisors LLC bought a new position in Quest Diagnostics in the 3rd quarter worth about $1,452,000. Ethic Inc. grew its position in Quest Diagnostics by 144.2% during the 3rd quarter. Ethic Inc. now owns 14,424 shares of the medical research company’s stock valued at $2,749,000 after purchasing an additional 8,518 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in Quest Diagnostics by 88.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 24,167 shares of the medical research company’s stock valued at $4,341,000 after purchasing an additional 11,351 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on DGX shares. Mizuho upped their target price on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a report on Monday, December 29th. UBS Group increased their target price on Quest Diagnostics from $180.00 to $190.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. Jefferies Financial Group lifted their target price on Quest Diagnostics from $200.00 to $215.00 and gave the stock a “buy” rating in a report on Tuesday, October 21st. Finally, Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Saturday. Seven research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Quest Diagnostics has a consensus rating of “Hold” and a consensus target price of $197.27.

Quest Diagnostics Stock Performance

DGX opened at $189.27 on Monday. The company’s 50 day moving average is $181.90 and its 200 day moving average is $179.84. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. The company has a market cap of $21.05 billion, a price-to-earnings ratio of 22.21, a PEG ratio of 2.41 and a beta of 0.64. Quest Diagnostics Incorporated has a 12-month low of $150.14 and a 12-month high of $197.55.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.09. The business had revenue of $2.82 billion for the quarter, compared to analysts’ expectations of $2.73 billion. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The company’s revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.30 EPS. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 13th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Tuesday, January 13th. This represents a $3.20 annualized dividend and a dividend yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is 37.56%.

Insider Buying and Selling

In related news, CEO J. E. Davis sold 55,093 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $192.22, for a total transaction of $10,589,976.46. Following the completion of the transaction, the chief executive officer directly owned 120,480 shares in the company, valued at approximately $23,158,665.60. The trade was a 31.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mark E. Delaney sold 7,946 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $187.35, for a total transaction of $1,488,683.10. Following the completion of the sale, the senior vice president directly owned 7,530 shares of the company’s stock, valued at $1,410,745.50. This represents a 51.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 65,771 shares of company stock valued at $12,588,676 in the last 90 days. Corporate insiders own 8.16% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.